Table 1.

Main clinical trial results concerning EGFR mutant lung cancer

Clinical trial	Clinical trial stage	Patients number of EGFR mutation	Treatment strategy	Key results
Checkmate 057 [2]	Phase 3	82	Nivolumab versus docetaxe	No PFS or OS benefit from nivolumab in EGFR mutation patients
Keynote 010 [7]	Phase 2/3	86	Pembrolizumab versus docetaxel	No PFS or OS benefit from pembrolizumab in EGFR mutation patients
OAK [4]	Phase 3	42	Atezolizumab versus docetaxel	EGFR mutant patients failed to prolong OS from atezolizumab comparing with docetaxel
NCT0287994	Phase 2	11	Pembrolizumab in TKI-naive patients with EGFR mutaiton, adcanced NSCLC, and PD-L1 positive tumors	None of the patients with EGFR-mutant lung cancer responded to pembrolizumab
Retrospective analysis [8]	-	28	Anti-PD-1/PD-L1 therapy	Only one patient response to anti-PD-1/PD-L1 therapy (The objective responses is 3.6%)
Pooled analysis 1 [9]	-	186	Anti-PD-1/PD-L1 therapy verus docetaxel	Anti-PD-1/PD-L1 therapy can’t improve the OS of patients with EGFR mutation
Pooled analysis 2 [10]	-	271	Anti-PD-1/PD-L1 therapy verus docetaxel	Anti-PD-1/PD-L1 therapy can’t improve the OS of patients with EGFR mutation